FY2028 EPS Estimates for Chimerix, Inc. (NASDAQ:CMRX) Decreased by Capital One Financial

Chimerix, Inc. (NASDAQ:CMRX) – Capital One Financial dropped their FY2028 EPS estimates for Chimerix in a report released on Wednesday, May 1st. Capital One Financial analyst N. Quibria now anticipates that the biopharmaceutical company will post earnings per share of $0.07 for the year, down from their prior forecast of $0.13. The consensus estimate for Chimerix’s current full-year earnings is ($0.77) per share.

Chimerix (NASDAQ:CMRX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 39.62% and a negative net margin of 25,337.96%. During the same period in the prior year, the company posted ($0.24) EPS.

A number of other equities research analysts also recently weighed in on CMRX. StockNews.com downgraded shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Chimerix in a research report on Friday, March 1st. Finally, Wedbush restated an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a research report on Monday, February 12th.

Chimerix Stock Performance

Shares of NASDAQ:CMRX opened at $0.95 on Friday. The stock has a market capitalization of $85.41 million, a P/E ratio of -1.02 and a beta of 1.13. Chimerix has a 1-year low of $0.88 and a 1-year high of $1.57. The business has a 50-day moving average price of $1.04 and a two-hundred day moving average price of $1.00.

Institutional Trading of Chimerix

Hedge funds have recently bought and sold shares of the stock. Pale Fire Capital SE increased its position in shares of Chimerix by 113.6% during the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 112,318 shares in the last quarter. Vestal Point Capital LP bought a new position in Chimerix during the 4th quarter worth about $1,348,000. Vance Wealth Inc. acquired a new stake in shares of Chimerix in the 4th quarter valued at about $46,000. Assenagon Asset Management S.A. lifted its holdings in shares of Chimerix by 17.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock valued at $481,000 after purchasing an additional 72,719 shares in the last quarter. Finally, RA Capital Management L.P. acquired a new position in shares of Chimerix during the third quarter worth about $6,240,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.